SOMNUM—A Revolutionary Polysomnography Reader Software

HoneyNaps, a South Korean healthcare startup, is introducing a new revolutionary medical software designed to analyze polysomnographic readings in under five minutes by employing AI. 

The software called SOMNUM can perform an accurate in-debt analysis of recorded sleep patterns with the help of artificial intelligence algorithms that are based on deep learning techniques.  

Furthermore, the American Academy of Sleep Medicine confirms scientists have recognized AI’s potential significance in helping patients get more effective treatment of sleep disturbances.

So, SOMNUM can not only diagnose the existing sleep disturbances but also recognize “sleep disorders in the making.” In other words, it helps in predicting and preventing these disorders. 

This innovation comes at a perfect time, considering the boost that the pandemic has given to the development of all kinds of sleep disorders, including insomnia (coronasomnia).  

In fact, because of the pandemic, fighting sleep disturbances became a $76 billion-worth market worldwide in 2020, with a predicted annual growth of no less than 14%. 

The same dynamic is detected in the global value of the sleep aids market, including over-the-counter sleep aids, whose sales skyrocketed to $81.2 billion last year.

Today, there are more than 100 million sleep disorder sufferers around the globe, and a polysomnography test is by far the best method to diagnose them. 

Before SOMNUM, sleep specialists (somnologists) needed almost four hours to analyze the results of polysomnography sleep monitoring. However, with the software, the analysis can be done in less than five minutes.   

What’s more, SOMNUM works on multiple channels and has a large capacity for signal analysis. All this results in more accurate interpretations than the currently used Auto-Scoring.

So when can we expect this innovative method of diagnosis to help US insomniacs, doctors, and sleep researchers? Currently, SOMNUM is being reviewed by the FDA (The Food and Drug Administration). If approved, the AI-backed software will likely enter the US market in 2022.